BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AMG 410 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AMG 410\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07094113-2346@assetmemo.bio
DTSTAMP:20261121T010126Z
DTSTART;VALUE=DATE:20280418
DTEND;VALUE=DATE:20280419
SUMMARY:AMG 410: Phase 1 readout est. (NCT07094113)
DESCRIPTION:AMG 410\, phase 1.\nStudy: AMG 410 Alone and in Combination Wit
 h Other Agents in Participants With KRAS Altered Advanced or Metastatic So
 lid Tumors\nEstimated primary completion: 18 April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/amg-410#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07094113
URL:https://assetmemo.bio/drug/amg-410#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
